Advertisement
Research Article| Volume 79, ISSUE 4, P349-356, October 2019

Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: A meta-analysis of findings

  • Author Footnotes
    1 These authors contributed equally to the work.
    Zhengwei Liu
    Footnotes
    1 These authors contributed equally to the work.
    Affiliations
    The Institute of TB Control, Zhejiang Provincial Center for Disease Control and Prevention, No. 3399, Binsheng road, Binjiang District, Hangzhou 310005, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to the work.
    Huali Dong
    Footnotes
    1 These authors contributed equally to the work.
    Affiliations
    Department of Clinical Laboratory, Zhejiang Xiao Shan Hospital, Hangzhou, China
    Search for articles by this author
  • BeiBei Wu
    Affiliations
    The Institute of TB Control, Zhejiang Provincial Center for Disease Control and Prevention, No. 3399, Binsheng road, Binjiang District, Hangzhou 310005, China
    Search for articles by this author
  • Mingwu Zhang
    Affiliations
    The Institute of TB Control, Zhejiang Provincial Center for Disease Control and Prevention, No. 3399, Binsheng road, Binjiang District, Hangzhou 310005, China
    Search for articles by this author
  • Yelei Zhu
    Affiliations
    The Institute of TB Control, Zhejiang Provincial Center for Disease Control and Prevention, No. 3399, Binsheng road, Binjiang District, Hangzhou 310005, China
    Search for articles by this author
  • Yu Pang
    Correspondence
    Corresponding authors.
    Affiliations
    National Clinical Laboratory on Tuberculosis, Beijing Key laboratory on Drug-resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, No. 9, Beiguan Street, Tongzhou District, Beijing 101149, China
    Search for articles by this author
  • Xiaomeng Wang
    Correspondence
    Corresponding authors.
    Affiliations
    The Institute of TB Control, Zhejiang Provincial Center for Disease Control and Prevention, No. 3399, Binsheng road, Binjiang District, Hangzhou 310005, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to the work.
Published:August 07, 2019DOI:https://doi.org/10.1016/j.jinf.2019.08.004
Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: A meta-analysis of findings
Previous ArticleBody composition changes successfully classify prognosis in patients with mycobacterium avium complex lung disease
Next ArticleImpact of point-of-care testing for respiratory viruses on antibiotic use in adults with exacerbation of airways disease

      Highlights

      • •
        Only 77% of RR-TB cases were MDR-TB; thus RR-TB cannot predict INH resistance in China.
      • •
        Greater MDR-TB prevalence was seen in previously treated versus new RR-TB cases.
      • •
        The prevalence of RR-TB exhibited great diversity across regions in China.

      Summary

      Objectives

      Systematic review of multidrug-resistant tuberculosis (MDR-TB) prevalence among rifampicin (RIF)-resistant tuberculosis (RR-TB) patients in 34 provinces of China was conducted to correlate RIF resistance with concurrent isoniazid (INH) resistance.

      Methods

      Database searches (PubMed, Embase, China National Knowledge Infrastructure, Chinese Scientific Journal, Wanfang), identified drug resistance surveillance studies conducted between January 1, 2000 and June 30, 2018. Of 1554 records, random-effects meta-analysis of 34 studies of adequate methodological quality yielded 108,366 TB cases for MDR-TB prevalence analysis of RR-TB cases.

      Results

      MDR-TB prevalence among RR-TB cases varied from 57% (Xinjiang; 95% CI 47%, 67%) to 95% (Taiwan; 95% CI 92%, 98%), for a pooled national rate of 77% (95% CI 75%, 80%). Subgroup and meta-regression analyses revealed greater MDR-TB prevalence in previously treated versus new RR-TB cases (P < 0.001), with no significant differences of regional initial drug resistance rates or sampling methods. Regional MDR-TB prevalence among RR-TB cases was lowest (69%) in the Northeast Region (95% CI 65%, 73%) and highest (90%) in Hong Kong, Macao and Taiwan (95% CI 81%, 98%).

      Conclusions

      In China, ∼77% of RR-TB cases are MDR-TB. Thus, RIF resistance cannot effectively predict MDR-TB. Highly variable RR-TB prevalence across China warrants improved TB management.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization; 2018. WHO/HTM/TB/2018.13.

        View in Article
        • Zhao Y.
        • Xu S.
        • Wang L.
        • Chin D.P.
        • Wang S.
        • Jiang G.
        • et al.
        National survey of drug-resistant tuberculosis in China.
        New Engl J Med. 2012; 366 (PubMed PMID:22670902): 2161-2170https://doi.org/10.1056/NEJMoa1108789
        View in Article
        • Schon T.
        • Miotto P.
        • Koser C.U.
        • Viveiros M.
        • Bottger E.
        • Cambau E.
        Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives.
        Clin Microbiol Infect. 2017; 23 (PubMed PMID:27810467. Epub 2016/11/05. eng): 154-160https://doi.org/10.1016/j.cmi.2016.10.022
        View in Article
        • Abubakar I.
        • Zignol M.
        • Falzon D.
        • Raviglione M.
        • Ditiu L.
        • Masham S.
        • et al.
        Drug-resistant tuberculosis: time for visionary political leadership.
        Lancet Infect Dis. 2013; 13 (PubMed PMID:23531391. Epub 2013/03/28. eng): 529-539https://doi.org/10.1016/S1473-3099(13)70030-6
        View in Article
        • Kendall E.A.
        • Fofana M.O.
        • Dowdy D.W.
        Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.
        Lancet Respir Med. 2015; 3 (PubMed PMID:26597127. Pubmed Central PMCID: 4684734. Epub 2015/11/26. eng): 963-972https://doi.org/10.1016/S2213-2600(15)00458-0
        View in Article
        • Kim S.J.
        Drug-susceptibility testing in tuberculosis: methods and reliability of results.
        Eur Respir J. 2005; 25 (PubMed PMID:15738303. Epub 2005/03/02. eng): 564-569https://doi.org/10.1183/09031936.05.00111304
        View in Article
        • Pang Y.
        • Xia H.
        • Zhang Z.
        • Li J.
        • Dong Y.
        • Li Q.
        • et al.
        Multicenter evaluation of genechip for detection of multidrug-resistant mycobacterium tuberculosis.
        J Clin Microbiol. 2013; 51 (PubMed PMID:23515537. Pubmed Central PMCID: Pmc3716084. Epub 2013/03/22. eng): 1707-1713https://doi.org/10.1128/JCM.03436-12
        View in Article
        • Pai M.
        • Schito M.
        Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects.
        J Infect Dis. 2015; 211 (PubMed PMID:25765103. Pubmed Central PMCID: 4366576. Epub 2015/03/15. eng): S21-S28https://doi.org/10.1093/infdis/jiu803
        View in Article
        • World Health Organization
        The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin: policy update.
        World Health Organization, Geneva, Switzerland2016
        View in Article
        • World Health Organization
        Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update.
        World Health Organization, Geneva, Switzerland2013
        View in Article
        • Boehme C.C.
        • Nabeta P.
        • Hillemann D.
        • Nicol M.P.
        • Shenai S.
        • Krapp F.
        • et al.
        Rapid molecular detection of tuberculosis and rifampin resistance.
        New Engl J Med. 2010; 363 (PubMed PMID:20825313. Pubmed Central PMCID: 2947799): 1005-1015https://doi.org/10.1093/infdis/jiu803
        View in Article
        • Chang K.
        • Lu W.
        • Wang J.
        • Zhang K.
        • Jia S.
        • Li F.
        • et al.
        Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis.
        J Infect. 2012; 64 (PubMed PMID:22381459. Epub 2012/03/03. eng): 580-588https://doi.org/10.1016/j.jinf.2012.02.012
        View in Article
        • Traore H.
        • Fissette K.
        • Bastian I.
        • Devleeschouwer M.
        • Portaels F.
        Detection of rifampicin resistance in mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance.
        Int J Tuberc Lung Dis. 2000; 4 (PubMed PMID:10815743): 481-484
        View in Article
        • Ahmad S.
        • Mokaddas E.
        • Fares E.
        Characterization of rpoB mutations in rifampin-resistant clinical mycobacterium tuberculosis isolates from Kuwait and Dubai.
        Diagn Microbiol Infect Dis. 2002; 44 (PubMed PMID:12493171): 245-252
        View in Article
        • Mukinda F.K.
        • Theron D.
        • van der Spuy G.D.
        • Jacobson K.R.
        • Roscher M.
        • Streicher E.M.
        • et al.
        Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.
        Int J Tuberc Lung Dis. 2012; 16 (PubMed PMID:22236920. Pubmed Central PMCID: 3712259. Epub 2012/01/13. eng): 196-202https://doi.org/10.5588/ijtld.11.0116
        View in Article
        • Meyssonnier V.
        • Bui T.V.
        • Veziris N.
        • Jarlier V.
        • Robert J.
        Rifampicin mono-resistant tuberculosis in France: a 2005–2010 retrospective cohort analysis.
        BMC Infect Dis. 2014; 14 (PubMed PMID:24410906. Pubmed Central PMCID: 3898244. Epub 2014/01/15. eng): 18https://doi.org/10.1186/1471-2334-14-18
        View in Article
        • Du J.
        • Pang Y.
        • Liu Y.
        • Mi F.
        • Xu S.
        • Li L.
        Survey of tuberculosis hospitals in China: current status and challenges.
        PLoS ONE. 2014; 9 (PubMed PMID:25365259. Pubmed Central PMCID: 4218826. Epub 2014/11/05. eng)e111945https://doi.org/10.1371/journal.pone.0111945
        View in Article
        • Noubiap J.J.
        • Nansseu J.R.
        • Nyaga U.F.
        • Nkeck J.R.
        • Endomba F.T.
        • Kaze A.D.
        • et al.
        Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis.
        Lancet Glob Health. 2019; 7 (PubMed PMID:30819531. Epub 2019/03/02. eng): e448-ee60https://doi.org/10.1016/S2214-109X(18)30487-X
        View in Article
        • Wang Q.
        • Ma D.
        • Liu J.
        • Yao S.
        • Kan X.
        • Bao F.
        • et al.
        Analysis of drug resistance baseline in smear positive pulmonary tuberculosis patients in Anhui province.
        Chin J Antitubercul. 2018; 40: 825-833
        View in Article
        • An Y.
        • Ding B.
        • Zhu J.
        • Xin Q.
        • He X.
        • Jin M.
        • et al.
        Report of who survey on drug-resistant tuberculosis in Beijing.
        Chin J Antitubercul. 2007; 29: 475-478
        View in Article
        • Liu J.
        • Jing K.
        • Liu Y.
        • Chen L.
        • Hu D.
        • Shen J.
        • et al.
        Analysis of tuberculosis drug resistance test results in Chongqing municipality in 2005.
        Lab Med Clin. 2009; 6: 963-965
        View in Article
        • Chen Q.
        • Lin S.
        • Liang Q.
        • Wei S.
        • Zhao Y.
        • Lin J.
        • et al.
        Tuberculosis drug resistance survillance report in Fujian province.
        Chin J Antitubercul. 2013; 35: 511-515
        View in Article
        • Si H.
        • Li Q.
        • Mu Z.
        • Liang C.
        • Yang Q.
        • Xie Z.
        • et al.
        Analysis of anti-TB drug resistance surveillance in Linxia, Ganan and Dingxi in Gansu province.
        Chin J Antitubercul. 2009; 31: 206-209
        View in Article
        • Zhong Q.
        • Qian M.
        • Li J.
        • Chen Q.
        • Zhou W.
        • Jiang Y.
        • et al.
        Study on drug resistance surveillance of tuberculosis in Guangdong province.
        Chin J Antitubercul. 2001; 23: 6-9
        View in Article

      25. Luo D. Epidemic characteristics of drug-resistant tuberculosis and genotyping of mycobacterium tuberculosis: Guangxi medical university; 2013.

        View in Article
        • Chen H.
        • Lei S.
        • Li Y.
        • Yuan W.
        Tuberculosis drug resistance surveillance in Guizhou province, 2012–2015.
        Mod Prevent Med. 2016; 43: 2442-2444
        View in Article
        • Huang J.
        • Chen Y.
        • Xiong C.
        • Wang C.
        • Fu C.
        • Luo X.
        Analysis of results of tuberculosis drug resistance monitoring in Hainan in 2015.
        China Trop Med. 2017; 17: 216-220
        View in Article
        • Li Y.
        • Cao X.
        • Li S.
        • Wang H.
        • Wei J.
        • Liu P.
        • et al.
        Characterization of mycobacterium tuberculosis isolates from Hebei, China: genotypes and drug susceptibility phenotypes.
        BMC Infect Dis. 2016; 16 (PMID:26939531): 1-11https://doi.org/10.1186/s12879-016-1441-2
        View in Article
        • Xie Y.
        • Li F.
        • Yan X.
        Who TB drug resistant survey in Heilongjiang province.
        Chin J Antitubercul. 2008; 30: 395-398
        View in Article
        • Du C.
        • Wang G.
        • Xu J.
        • Wang G.
        • Hu H.
        • Zhen X.
        • et al.
        The study on the second round surveillance of drug resistance in tuberculosis and its trends in Henan, China.
        Chin J Antitubercul. 2006; 28: 95-100
        View in Article
        • Kam K.M.
        • Yip C.W.
        Surveillance of mycobacterium tuberculosis drug resistance in Hong Kong, 1986–1999, after the implementation of directly observed treatment.
        Int J Tuberc Lung Dis. 2001; 5 (PMID:11573892): 815
        View in Article
        • Li G.
        • Wu X.
        • Zhang D.
        • Zhou L.
        • Li K.
        • Liu X.
        • et al.
        Surveillance of drug resistant tuberculosis in Hubei, China.
        Chin J Tuberc Respir Dis. 2002; 25: 723-726
        View in Article
        • Yang A.
        • Zhou L.
        • Xu Z.
        • Tan Y.
        • Yi H.
        • Zhang C.
        • et al.
        Retrospective study on the resistance characteristics and associated factors of four first-line anti-tuberculosis drugs in hunan province, china.
        Chin J Zoonoses. 2018; 34: 396-403
        View in Article
        • Wang S.
        • Liu Y.
        • Jiang G.
        • Liu Y.
        • Fu Y.
        • Duanmu H.
        Evaluation of who drug resistance surveillance on tuberculosis in China.
        Chin J Lab Med. 2007; 30: 863-866
        View in Article
        • Yang D.
        • Shao Y.
        • Yu H.
        • Wang J.
        • Xu W.
        • Lu W.
        • et al.
        Epidemiology of anti-tuberculosis drug resistance in Jiangsu province.
        Acta Univ Med Nanjing (Nat Sci). 2011; 31: 1007-1010
        View in Article
        • Zhao J.
        • He W.
        • Qiu L.
        • Peng X.
        • Zen Y.
        • Huang R.
        Drug resistance of mycobacterium tuberculosis isolated from some areas of Jiangxi.
        Dis Surveil. 2016; 31: 1061-1063
        View in Article
        • Yuan Y.
        • Yang X.
        • Yang G.
        • Li X.
        • Wang B.
        • Zhang W.
        • et al.
        Drug resistance surveillance of tuberculosis in in Jilin province.
        Chin J Public Health Eng. 2015; 14: 70-75
        View in Article
        • Zhong W.
        • Yang L.
        • He L.
        • Cao H.
        • Wang M.
        Drug resistance situation and related factors of pulmonary tuberculosis in Liaoning.
        China Trop Med. 2017; 17: 221-225
        View in Article
        • Zhang S.
        • Liu Y.
        Epidemiological survey on the trend of drug resistance of mycobacterium tuberculosis complex in Macao during 2001 to 2005.
        Chin J Tuberc Respir Dis. 2007; 30: 411-414
        View in Article
        • Wang X.
        • Wang X.
        • Xiao H.
        • Lei J.
        • Pan L.
        • Shi F.
        • et al.
        Survey of drug-resistant mycobacterium tuberculosis in Ningxia.
        Chin J Tuberc Respir Dis. 2015; 38: 738-740
        View in Article
        • Shen X.
        • Jiang M.
        • Wang Z.
        • Li B.
        • Ma B.
        • Wen G.
        • et al.
        Current situation of drug resistance of 236 mycobacterium tuberculosis from Qinghai.
        Chin J Dis Control Prev. 2017; 21: 353-356
        View in Article
        • Zhang T.
        • Liu W.
        • Li Y.
        • Deng Y.
        • Sun X.
        • Liu C.
        • et al.
        Analysis of drug resistance surveillance of tuberculosis in Shaanxi.
        China Trop Med. 2017; 17: 226-230
        View in Article
        • Li J.
        • Li X.
        • Gen H.
        • Tao W.
        • Yu C.
        Epidemic status of drug-resistant mycobacterium tuberculosis in Shandong province, China.
        Chin J Tuberc Respir Dis. 2013; 36: 667-670
        View in Article
        • Mei J.
        • Shen X.
        • Shen M.
        • Gui X.
        • Sun B.
        Survey of drug-resistant M . tuberculosis in Shanghai, China.
        Chin J Antitubercul. 2007; 29: 395-398
        View in Article
        • Guan P.
        • Zhi X.
        Analysis of drug resistance of tuberculosis patients in Taiyuan from 2011 to 2013.
        Chin Remedies Clin. 2015; 15: 1577-1580
        View in Article
        • Long B.
        • Yang J.
        • Wang W.
        • Gao W.
        • Chen Q.
        • Yang R.
        • et al.
        Drug Resistance of mycobacterium tuberculosis in Sichuan.
        J Prev Med Inf. 2014; 30: 430-433
        View in Article
        • Jou R.
        • Chuang P.
        • Wu Y.
        • Yan J.
        • Luh K.
        Drug-resistant mycobacterium tuberculosis, Taiwan.
        Emerg Infect Dis. 2006; 12: 871-872
        View in Article
        • Li G.
        Studies on risk factors for drug-resistant tuberculosis and molecular mechanisms of drug-resistant mycobacterium tuberculosis.
        Tianjin Medical University, Tianjin2010
        View in Article
        • Shi L.
        • Wei S.
        Drug susceptibility test of mycobacterium tuberculosis: analysis of 217 clinical isolates in Tibet.
        Chin J Nosocomiol. 2009; 19: 2476-2477
        View in Article
        • Jia W.
        • Zhang W.
        • Gu X.
        • Yu J.
        • Ayinuer
        • Liu N.
        • et al.
        The report of who drug resistance surveillance on tuberculosis, Xinjiang.
        Chin J Antitubercul. 2008; 30: 307-310
        View in Article
        • Xu L.
        • Chen L.
        • Ma L.
        • Yang H.
        Drug resistance surveillance of tuberculosis in in Yunnan province.
        J Prev Med Inf. 2015; 31: 933-937
        View in Article
        • Chen S.
        • Wu B.
        • Liu Z.
        • He H.
        • Pan A.
        • Wang F.
        • et al.
        An analysis on the epidemic characteristics of tuberculosis drug.
        Prevent Med. 2016; 28: 757-761
        View in Article
        • Ginsberg A.M.
        • Spigelman M.
        Challenges in tuberculosis drug research and development.
        Nat Med. 2007; 13 (PubMed PMID:17342142. Epub 2007/03/08. eng): 290-294https://doi.org/10.1038/nm0307-290
        View in Article
        • Jenkins H.E.
        • Zignol M.
        • Cohen T.
        Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994–2009.
        PLoS ONE. 2011; 6 (PubMed PMID:21829557. Pubmed Central PMCID: 3146514. Epub 2011/08/11. eng): e22927https://doi.org/10.1371/journal.pone.0022927
        View in Article
        • Mukherjee J.S.
        • Rich M.L.
        • Socci A.R.
        • Joseph J.K.
        • Viru F.A.
        • Shin S.S.
        • et al.
        Programmes and principles in treatment of multidrug-resistant tuberculosis.
        Lancet. 2004; 363 (PubMed PMID:14962530. Epub 2004/02/14. eng): 474-481https://doi.org/10.1016/S0140-6736(04)15496-2
        View in Article
        • Wang L.
        • Zhang H.
        • Ruan Y.
        • Chin D.P.
        • Xia Y.
        • Cheng S.
        • et al.
        Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data.
        Lancet. 2014; 383 (PubMed PMID:24650955. Epub 2014/03/22. eng): 2057-2064https://doi.org/10.1016/S0140-6736(13)62639-2
        View in Article
        • Denkinger C.M.
        • Grenier J.
        • Stratis A.K.
        • Akkihal A.
        • Pant-Pai N.
        • Pai M.
        Mobile health to improve tuberculosis care and control: a call worth making.
        Int J Tuberc Lung Dis. 2013; 17 (PubMed PMID:23541232. Epub 2013/04/02. eng): 719-727https://doi.org/10.5588/ijtld.12.0638
        View in Article

      Article info

      Publication history

      Published online: August 07, 2019
      Accepted: August 4, 2019

      Identification

      DOI: https://doi.org/10.1016/j.jinf.2019.08.004

      Copyright

      © 2019 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX